Single-Dose Pharmacokinetics, Pharmacodynamics, Tolerability, and Safety of BAY 60-5521, a Potent Inhibitor of Cholesteryl Ester Transfer Protein
Phase of Trial: Phase I
Latest Information Update: 12 Aug 2011
At a glance
- Drugs BAY 605521 (Primary)
- Indications Dyslipidaemias
- Focus Adverse reactions
- 12 Aug 2011 Results published in the British Journal of Clinical Pharmacology.